文献速递衰弱、肌少症与跌倒老年慢病共病管理

SDOC与AWGS 2019肌少症标准对老年心衰患者预后的价值比较

Prognostic Value of Sarcopenia Definitions and Outcomes Consortium Criteria in Older Patients with Heart Failure.
PubMed 文献 · J Am Med Dir Assoc · 2024-11-12

本研究为FRAGILE-HF研究的post hoc分析,纳入1282例≥65岁住院心衰患者,比较SDOC与AWGS 2019肌少症诊断标准对2年全因死亡的预后价值。

要点

  • SDOC肌少症标准可对老年心衰患者进行死亡风险分层。
  • SDOC标准预后能力与AWGS 2019标准相当,AUC分别为0.697和0.703。
  • SDOC标准下肌少症组2年死亡风险显著升高(HR 1.89)。

核心结论

  • 在老年心衰患者中,SDOC肌少症诊断标准有助于风险分层,其预后能力与AWGS 2019标准相当。

研究设计与样本

  • FRAGILE-HF研究的post hoc分析,为前瞻性、多中心、观察性研究。
  • 纳入日本15家医院1282例≥65岁因心衰住院的患者。

主要发现

  • SDOC标准下可能肌少症357例,肌少症786例。
  • Kaplan-Meier分析显示组间生存差异显著。

关键数值与推荐

  • 肌少症诊断分别依据AWGS 2019和SDOC定义,SDOC标准下分为非肌少症、可能肌少症和肌少症三组。
  • 主要结局为2年死亡率。

临床怎么用

  • 临床可运用SDOC标准对老年心衰住院患者进行肌少症评估以辅助死亡风险分层。
  • SDOC与AWGS 2019标准预后价值相当,选择时可结合功能评估与肌肉量测量条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Asian Working Group for Sarcopenia in 2019 (AWGS 2019) emphasized muscle mass measurements. In contrast, the Sarcopenia Definitions and Outcomes Consortium (SDOC) prioritizes functional strength and mobility. Therefore, this study aimed to compare the prognostic utility of the SDOC and AWGS 2019 criteria for all-cause mortality in older patients with heart failure. DESIGN: A post hoc analysis of the Prevalence and Prognostic Value of Physical and Social Frailty in Geriatric Patients Hospitalized for Heart Failure (FRAGILE-HF) study, a prospective, multicenter, observational study. SETTING AND PARTICIPANTS: Patients aged ≥65 years hospitalized for heart failure across 15 hospitals in Japan. METHODS: Sarcopenia was diagnosed according to the AWGS 2019 and SDOC definitions. According to the SDOC criteria and by integrating insights from previous research, patients were categorized into nonsarcopenia, possible sarcopenia, and sarcopenia groups. The primary outcome was 2-year mortality. RESULTS: Of the 1282 study patients, possible sarcopenia and sarcopenia were diagnosed in 357 and 786 individuals, respectively. Kaplan-Meier analysis revealed a significant difference between the groups. Adjusted Cox proportional hazards analysis indicated a significant stepwise association between sarcopenic status and mortality risk (possible sarcopenia: hazard ratio, 1.22; 95% CI, 0.66-2.28; P = .525; sarcopenia: hazard ratio, 1.89; 95% CI, 1.08-3.34; P = .027). When sarcopenia defined by the SDOC and AWGS 2019 criteria was added to the model incorporating conventional risk factors, no significant difference was observed in the prognostic capabilities between the 2 models (net reclassification improvement, -0.009; 95% CI, -0.193 to 0.174; P = .920, with areas under the receiver operating characteristic curve of 0.697 for SDOC and 0.703 for AWGS 2019; P = .675). CONCLUSIONS AND IMPLICATIONS: Among older patients with heart failure, the SDOC criteria for sarcopenia diagnosis are useful for risk stratification and provide prognostic capabilities equivalent to those of the AWGS 2019 criteria.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Nakade T, Maeda D, Matsue Y, et al. Prognostic Value of Sarcopenia Definitions and Outcomes Consortium Criteria in Older Patients with Heart Failure. J Am Med Dir Assoc. 2024. PMID: 39542034. doi:10.1016/j.jamda.2024.105350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。